Trial Profile
A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2014
Price :
$35
*
At a glance
- Drugs CNV 2197944 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Peripheral neuropathies
- Focus Therapeutic Use
- Sponsors Convergence Pharmaceuticals
- 27 Sep 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 28 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 08 Jul 2013 Status changed to recruiting according to a Convergence Pharmaceuticals media release.